Literature DB >> 21936671

Screening for medullary thyroid carcinoma with serum calcitonin measurements in patients with thyroid nodules in the United States and Canada.

Gilbert H Daniels1.   

Abstract

BACKGROUND: Medullary thyroid carcinoma (MTC) is a rare thyroid malignancy with the potential for aggressive behavior. Measurement of serum calcitonin (Ct) in the thyroid nodule population is the most sensitive way to detect occult MTC. An important and controversial question is whether all patients with thyroid nodules should undergo Ct measurements to detect occult MTC.
SUMMARY: The prevalence of MTC detected by performing surgery on unselected individuals with thyroid nodules with elevated serum Ct is 0.4%. The central role of pentagastrin (PG) stimulation for triaging patients with minimally elevated serum Ct to prevent unnecessary surgery is reviewed. Data concerning a large reservoir of medullary thyroid microcarcinomas are discussed.
CONCLUSION: Given the unavailability of PG in the United States and Canada, the available data argue against routine Ct measurements in all individuals with thyroid nodules in these countries because of the potential for unnecessary surgery and the uncertain benefit in diagnosing medullary microcarcinoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21936671     DOI: 10.1089/thy.2010.0297

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  10 in total

Review 1.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

2.  Correspondence (letter to the editor): Extremely low numbers of cases.

Authors:  Heinz-Harald Abholz; Elizabeth Bandeira-Echtler; Johannes Köbberling
Journal:  Dtsch Arztebl Int       Date:  2013-02-01       Impact factor: 5.594

3.  Stimulated calcitonin cut-offs by different tests.

Authors:  Laura Fugazzola
Journal:  Eur Thyroid J       Date:  2013-01-16

4.  Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL).

Authors:  M Angelyn Bethel; Rishi A Patel; Vivian P Thompson; Peter Merrill; Shelby D Reed; Yanhong Li; Sara Ahmadi; Brian G Katona; Stephanie M Gustavson; Peter Ohman; Nayyar Iqbal; Robert F Gagel; Adrian F Hernandez; John B Buse; Rury R Holman
Journal:  Diabetes Care       Date:  2019-04-22       Impact factor: 19.112

Review 5.  Biologic and Clinical Perspectives on Thyroid Cancer.

Authors:  James A Fagin; Samuel A Wells
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

6.  Timing and extent of thyroid surgery for gene carriers of hereditary C cell disease--a consensus statement of the European Society of Endocrine Surgeons (ESES).

Authors:  Bruno Niederle; Frédéric Sebag; Michael Brauckhoff
Journal:  Langenbecks Arch Surg       Date:  2013-12-03       Impact factor: 3.445

7.  Calcitonin testing for detection of medullary thyroid cancer in people with thyroid nodules.

Authors:  Hans Hg Verbeek; Jan Willem B de Groot; Wim J Sluiter; Anneke C Muller Kobold; Edwin R van den Heuvel; John Tm Plukker; Thera P Links
Journal:  Cochrane Database Syst Rev       Date:  2020-03-16

Review 8.  Thyroid nodules in pediatrics: which ones can be left alone, which ones must be investigated, when and how.

Authors:  Andrea Corrias; Alessandro Mussa
Journal:  J Clin Res Pediatr Endocrinol       Date:  2013

9.  LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations.

Authors:  G H Daniels; L Hegedüs; S P Marso; M A Nauck; B Zinman; R M Bergenstal; J F E Mann; J Derving Karsbøl; A C Moses; J B Buse; R M Tuttle
Journal:  Diabetes Obes Metab       Date:  2015-02-23       Impact factor: 6.577

10.  Twenty years of experience with the preoperative diagnosis of medullary cancer in a moderately iodine-deficient region.

Authors:  Tamas Solymosi; Gyula Lukacs Toth; Dezso Nagy; Istvan Gal
Journal:  Int J Endocrinol       Date:  2013-03-06       Impact factor: 3.257

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.